Louisa F. Alim

Woolloongabba, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 12 publications

Engineering Human Hematopoietic Stem and Progenitor Cells for Antigen Expression in Antigen-Presenting Cells.

Engineering Human Hematopoietic Stem and Progenitor Cells for Antigen Expression in Antigen-Presenting Cells.

Journal: Human gene therapy

Published: August 24, 2026

The GFI1-FOXO1 axis regulates NK cell maturation and function.

The GFI1-FOXO1 axis regulates NK cell maturation and function.

Journal: Nature communications

Published: August 06, 2025

Highlights of 2024: Cytokines and ligands modulating NK cell effector functions.

Highlights of 2024: Cytokines and ligands modulating NK cell effector functions.

Journal: Immunology and cell biology

Published: March 06, 2025

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: January 08, 2025

Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapy.

Antigen presentation potential is variable among human ovarian tumour and syngeneic murine models and dictates pre-clinical outcomes of immunotherapy.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: November 27, 2024

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.

Enhancement of anti-sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2-targeted CAR.

Journal: Clinical and translational medicine

Published: August 23, 2024

A scalable, spin-free approach to generate enhanced induced pluripotent stem cell-derived natural killer cells for cancer immunotherapy.

A scalable, spin-free approach to generate enhanced induced pluripotent stem cell-derived natural killer cells for cancer immunotherapy.

Journal: Immunology and cell biology

Published: August 17, 2024

The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy.

The immune checkpoint TIGIT is upregulated on T cells during bacterial infection and is a potential target for immunotherapy.

Journal: Immunology and cell biology

Published: May 20, 2024

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.

TGF-β signalling limits effector function capacity of NK cell anti-tumour immunity in human bladder cancer.

Journal: EBioMedicine

Published: August 29, 2023

Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment.

Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment.

Journal: Current opinion in immunology

Published: August 04, 2023

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation.

Dichotomous outcomes of TNFR1 and TNFR2 signaling in NK cell-mediated immune responses during inflammation.

Journal: Nature communications

Published: June 28, 2023

miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration.

miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration.

Journal: Molecular therapy oncolytics

Published: April 28, 2023

Showing 1-12 of 12

Last Updated: 09/26/2026